TABLE 1.
Summary of agonist EC50 values for each assay
To directly compare peptidomimetic agonists within each assay, EC50 values were calculated, and 95% CI were determined. RTCA-peak, RTCA peak response; Percent Ca2+ response, percentage of cells with [Ca2+]i >200 nm within 3 min of agonist addition; Thermal hyperalgesia, in vivo thermal hyperalgesia response. ND, not determined.
| Agonist | Technique |
||||
|---|---|---|---|---|---|
| RTCA-peak EC50 (95% CI) | RTCA-AUC EC50 (95% CI) | ICW EC50 (95% CI) | Percent Ca2+ response EC50 (95% CI) | Thermal hyperalgesia EC50 (95% CI) | |
| 2-f-LIGRLO-NH2 | 235 nm (193–290 nm) | 114 nm (83–158 nm) | 314 nm (193–508 nm) | 0.84 μm (0.69–0.99 μm) | 7.4 μg (3.4–16.2 μg) |
| 2-at-LIGRL-NH2 | 314 nm (244–403 nm) | 106 nm (82–137 nm) | 458 nm (204 nm–1.03 μm) | 1.82 μm (1.47–2.25 μm) | 4.7 μg (2.0–10.7 μg) |
| 6-an-LIGRL-NH2 | 430 nm (350–529 nm) | 254 nm (197–328 nm) | 1.04 μm (358 nm–3.03 μm) | 2.60 μm (2.04–3.32 μm) | ND |